Bertelli E, Leonini S, Galimberti D, Moretti S, Tinturini R, Hadjistilianou T, De Francesco S, Romano D G, Vallone I M, Cioni S, Gennari P, Galluzzi P, Grazzini I, Rossi S, Bracco S
From the Department of Molecular and Developmental Medicine (E.B., S.R.), University of Siena, Siena, Italy.
Units of Neuroimaging and Neurointervention (S.L., D.G.R., I.M.V., S.C., P. Gennari, P. Galluzzi, I.G., S.B.).
AJNR Am J Neuroradiol. 2016 Jul;37(7):1289-95. doi: 10.3174/ajnr.A4741. Epub 2016 Feb 25.
Intra-arterial chemotherapy for retinoblastoma is not always a straightforward procedure, and it may require an adaptable approach. This study illustrates strategies used when the ophthalmic artery is difficult to catheterize or not visible, and it ascertains the effectiveness and safety of these strategies.
A retrospective study was performed on a series of 108 eyes affected by intraocular retinoblastoma and selected for intra-arterial chemotherapy (follow-up range, 6-82 months). We recognized 3 different patterns of drug delivery: a fixed pattern through the ophthalmic artery, a fixed pattern through branches of the external carotid artery, and a variable pattern through either the ophthalmic or the external carotid artery.
We performed 448 sessions of intra-arterial chemotherapy, 83.70% of them through the ophthalmic artery and 16.29% via the external carotid artery. In 24.52% of eyes, the procedure was performed at least once through branches of the external carotid artery. In 73 eyes, the pattern of drug delivery was fixed through the ophthalmic artery; for 9 eyes, it was fixed through branches of the external carotid artery; and for 17 eyes, the pattern was variable. Statistical analysis did not show any significant difference in the clinical outcome of the eyes (remission versus enucleation) treated with different patterns of drug delivery. Adverse events could not be correlated with any particular pattern.
Alternative routes of intra-arterial chemotherapy for intraocular retinoblastoma appear in the short term as effective and safe as the traditional drug infusion through the ophthalmic artery.
视网膜母细胞瘤的动脉内化疗并非总是一个简单的过程,可能需要一种适应性的方法。本研究阐述了在眼动脉难以插管或不可见时所采用的策略,并确定了这些策略的有效性和安全性。
对一系列108只受眼内视网膜母细胞瘤影响并选择进行动脉内化疗的眼睛进行了回顾性研究(随访范围为6 - 82个月)。我们识别出3种不同的给药模式:通过眼动脉的固定模式、通过颈外动脉分支的固定模式以及通过眼动脉或颈外动脉的可变模式。
我们进行了448次动脉内化疗,其中83.70%通过眼动脉进行,16.29%通过颈外动脉进行。在24.52%的眼睛中,至少有一次通过颈外动脉分支进行该操作。在73只眼中,给药模式通过眼动脉固定;9只眼中,通过颈外动脉分支固定;17只眼中,模式是可变的。统计分析未显示不同给药模式治疗的眼睛(缓解与眼球摘除)的临床结果有任何显著差异。不良事件与任何特定模式均无关联。
眼内视网膜母细胞瘤动脉内化疗的替代途径在短期内似乎与通过眼动脉的传统药物输注一样有效和安全。